Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NEPHSTROM

Financiado

Cerrado

Novel Stromal Cell Therapy for Diabetic Kidney Disease

Type 2 diabetes will affect >500 million adults by 2040 and its secondary complications will generate enormous socioeconomic costs - in particular, diabetic kidney disease (DKD), which is already the most common cause of chronic k... ver más

31/10/2021

OLLSCOIL NA GAILLI...

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

UNIVERSITY OF GALWAY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 13 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-10-31

PHC-13-2014: New therapies for chronic non-commu...

I+D

Cerrada hace 10 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

13 Participantes

OLLSCOIL NA GAILLIMHE

1.44M€ | Lider

NHSBT

450.00K€ | Participante

Terumo BCT

599.81K€ | Participante

RESEARCH FOUNDATION OSPEDALE...

300.28K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2017-89782-R COMO MODELAR LA NEFROPATIA DIABETICA: RESTABLECIENDO EL EPIG... 182K€ Cerrado

RENOIR RENal prOgenItoRs as tools to understand kidney pathophysiol... 2M€ Cerrado

NEPHROTOOLS The potential of human kidney stem progenitor cells for use... 4M€ Cerrado

SEMA3C Genetic dissection of the SEMA3C Neuropilin 1 signalling pat... 185K€ Cerrado

ELECTRIC Efficacy of Leveraging Endocrine Therapies for Renoprotectio... 277K€ Cerrado

STELLAR Stem cell based therapy for kidney repair 10M€ Cerrado

Duración del proyecto: 78 meses Fecha Inicio: 2015-04-08
Fecha Fin: 2021-10-31

Líder del proyecto

UNIVERSITY OF GALWAY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Type 2 diabetes will affect >500 million adults by 2040 and its secondary complications will generate enormous socioeconomic costs - in particular, diabetic kidney disease (DKD), which is already the most common cause of chronic kidney disease. DKD is associated with greatly increased mortality and frequently progresses to end stage renal failure. Pharmacotherapy, dialysis and transplantation represent the mainstay treatments for DKD but are costly and provide only limited protection against adverse outcomes. Mesenchymal Stromal Cell (MSC) therapy is a promising approach to halting the progression of DKD toward end-stage renal failure and may also have ancillary benefits in Type 2 diabetes. In preliminary research, we have demonstrated that a single dose of MSC simultaneously improves kidney function (glomerular filtration rate and albuminuria) as well as hyperglycaemia in animals with DKD. NEPHSTROM will conduct a multi-centre, placebo-controlled clinical trial of a novel MSC therapy for stabilization of progressive DKD, leading to superior clinical outcomes and long-term socioeconomic benefit. A key enabler for this trial is a novel MSC population (CD362+MSC, trade name ORBCEL-M) which delivers higher purity and improved characterisation compared to conventional plastic-adherent MSC. The NEPHSTROM Phase 1b/2a clinical trial will investigate the safety, tolerability and preliminary efficacy of a single intravenous infusion of allogeneic ORBCEL-M versus placebo in adults with progressive DKD. NEPHSTROM investigators will also determine the bio-distribution, mechanisms of action, immunological effects and economic impacts associated with ORBCEL-M therapy for DKD. This research will critically inform the optimal design of subsequent Phase 3 trials of ORBCEL-M. Stabilising progressive DKD through NEPHSTROM’s next-generation MSC therapy will reduce the high all-cause mortality and end-stage renal failure risk in people with this chronic non-communicable disease

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores